References of "LANCELLOTTI, Patrizio"
     in
Bookmark and Share    
Peer Reviewed
See detailClub 35 Poster session 2: Thursday 4 December 2014, 08:30-18:00Location: Poster area.
Voilliot, D.; Magne, Jm; DULGHERU, Raluca Elena ULg et al

Poster (2014, December)

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailRecommandations européennes concernant la prise en charge de l'embolie pulmonaire.
MELISSOPOULOU, Maria ULg; ANCION, Arnaud ULg; LANCELLOTTI, Patrizio ULg

in Revue Medicale de Liege (2014), 69(11), 594-599

Detailed reference viewed: 81 (15 ULg)
Full Text
Peer Reviewed
See detailL'image du mois : Echocardiographie tridimensionnelle : une vue presque chirurgicale (2014).
JOACHIM, Sabrina ULg; NYSSEN, Astrid ULg; Henri, Christine et al

in Revue Médicale de Liège (2014), 69(10), 525

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailLe médicament du mois Combinaison fixe périndopril-indapamide-amlodipine (Triplixam®) pour le traitement de l’hypertension artérielle
SCHEEN, André ULg; LANCELLOTTI, Patrizio ULg; KRZESINSKI, Jean-Marie ULg

in Revue Médicale de Liège (2014), 69(10), 565-570

Triplixam® is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension : perindopril, an ... [more ▼]

Triplixam® is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension : perindopril, an angiotensin converting enzyme inhibitor, indapamide, un diuretic whith thiazide-like effects but also specific properties, and amlodipine, a long-acting calcium antagonist of the dihydropyridine family. The potential synergic action allows better control of blood pressure with once daily administration, while limiting the incidence of adverse events. Various presentations with different dosages are available to facilitate individualized therapy. Warnings and precautions for use of every molecule should of course be respected. Such a fixed dose combination should contribute to limit clinical inertia and to improve therapeutic compliance. [less ▲]

Detailed reference viewed: 286 (4 ULg)
Full Text
Peer Reviewed
See detail2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Elliott, Perry M.; Anastasakis, Aris; Borger, Michael A. et al

in European heart journal (2014), 35(39), 2733-79

Detailed reference viewed: 37 (0 ULg)
Full Text
Peer Reviewed
See detailESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.
Ryden, Lars; Grant, Peter J.; Anker, Stefan D. et al

in Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease (2014), 11(3), 133-73

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detail2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
Brignole, Michele; Auricchio, Angelo; Baron-Esquivias, Gonzalo et al

in Revista espanola de cardiologia (English ed.) (2014), 67(1), 58

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailRecommandations européennes pour la prise en charge des cardiopathies congénitales complexes de l'adulte
MILTNER, Béatrice ULg; LANCELLOTTI, Patrizio ULg; SEGHAYE, Marie-Christine ULg

in Revue Médicale de Liège (2014), 69(1), 16-25

THe number of patients with Grown-Up Congenital Heart disease (GUCH) consulting adult cardiologists is steadily increasing. These patients have either a non-diagnosed congenital heart disease revealed at ... [more ▼]

THe number of patients with Grown-Up Congenital Heart disease (GUCH) consulting adult cardiologists is steadily increasing. These patients have either a non-diagnosed congenital heart disease revealed at adulthood, or a diagnosed congenital heart disease for which one or multiple interventions have possibly been performed during childhood. In this article, we summarize the recommendations of the European Society of Cardiology of 2010 for complex congenital heart disease. [less ▲]

Detailed reference viewed: 123 (6 ULg)
Full Text
Peer Reviewed
See detailExpert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Plana, Juan Carlos; Galderisi, Maurizio; Barac, Ana et al

in Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2014), 27(9), 911-39

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailLa prevention des maladies cardiovasculaires est-elle encore utile chez la personne agee? Focus sur les antiagregants et les hypolipemiants.
RADERMECKER, Régis ULg; Lancellotti, Patrizio ULg

in Revue medicale de Liege (2014), 69(5-6), 318-22

The increase in life expectancy raises the difficult question of the most appropriate preventive medical therapy in the elderly. Indeed, beyond physiological age, comorbidities, contraindications and life ... [more ▼]

The increase in life expectancy raises the difficult question of the most appropriate preventive medical therapy in the elderly. Indeed, beyond physiological age, comorbidities, contraindications and life expectancy should be considered before starting any treatment. Cardiovascular disease remains the leading cause of death in our country, especially in the elderly. A preventive treatment aiming at controlling cardiovascular risk factors should be initiated based on the currently available evidence. We shall briefly discuss the value of cardiovascular prevention in the elderly and specifically focus on the use (or not) of antiplatelet agents and lipid-lowering drugs (i.e. statins). [less ▲]

Detailed reference viewed: 83 (8 ULg)
See detailTHE EACVI ECHOCARDIOGRAPHY TEXTBOOK
LANCELLOTTI, Patrizio ULg; HABIB, Gilbert; BADANO, L. et al

Book published by Oxford University Press (2014)

Detailed reference viewed: 18 (0 ULg)
See detailTHE EACVI HANDBOOK OF ECHOCARDIOGRAPHY
LANCELLOTTI, Patrizio ULg; COSYSNS, B.

Book published by Oxford University Press (2014)

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailWhen the heart has its reason: the Takotsubo Syndrome
DAVIN, Laurent ULg; LEGRAND, Victor ULg; LANCELLOTTI, Patrizio ULg et al

in Acta Psychiatrica Belgica (2014)

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailL'image du mois. Echocardiographie tridimensionnelle: une vue presque chirurgicale.
Joachim, S.; NYSSEN, Astrid ULg; Henri, C. et al

in Revue medicale de Liege (2014), 69(10), 525

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailCombinaison fixe perindopril-indapamide-amlodipine (Triplixam) pour le traitement de l'hypertension arterielle.
Scheen, André ULg; Lancellotti, Patrizio ULg; Krzesinski, Jean-Marie ULg

in Revue medicale de Liege (2014), 69(10), 565-70

Triplixam is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension: perindopril, an ... [more ▼]

Triplixam is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension: perindopril, an angiotensin converting enzyme inhibitor, indapamide, a diuretic whith thiazide-like effects but also specific properties, and amlodipine, a long-acting calcium antagonist of the dihydropyridine family. The potential synergic action allows better control of blood pressure with once daily administration, while limiting the incidence of adverse events. Various presentations with different dosages are available to facilitate individualized therapy. Warnings and precautions for use of every molecule should of course be respected. Such a fixed dose combination should contribute to limit clinical inertia and to improve therapeutic compliance. [less ▲]

Detailed reference viewed: 41 (0 ULg)
Full Text
Peer Reviewed
See detailLa fibrillation auriculaire: une epidemie du troisieme age?
Kulbertus, Henri ULg; Lancellotti, Patrizio ULg

in Revue medicale de Liege (2014), 69(5-6), 301-8

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. In its non valvular form, it appears as a disorder of the aged. Surprisingly, its incidence and prevalence have ... [more ▼]

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. In its non valvular form, it appears as a disorder of the aged. Surprisingly, its incidence and prevalence have constantly been on the rise over the last decades to the extent that some authors nowadays call this phenomenon an "emerging epidemic". The reasons for that proliferation are not entirely elucidated. Obesity, which has simultaneously and similarly increased in frequency, might have played a significant role. AF is frequently pauci-symptomatic in the aged and can easily go unrecognized. Yet, it entails a higher mortality rate, carries a significant risk of thrombo-embolic events, in particular strokes, and may lead to heart failure. We shall briefly review the current epidemiologic aspects of AF and evoke the possible role of obesity. We shall then discuss the therapy of this disorder with a particular attention to the new oral anticoagulants. [less ▲]

Detailed reference viewed: 53 (3 ULg)
Full Text
Peer Reviewed
See detailRecommadantions européennes concernant la thérapie de resynchronisation cardiaque
ROBINET, Sébastien ULg; DELCOUR, Alexandre ULg; Lancellotti, Patrizio ULg

in Revue Médicale de Liège (2014), 69(4), 180-187

Cardiac resynchronization therapy (CRT) is one of the most successful heart failure therapies to emerge in the last 25 years; it is applicable to > 25-30% of patients with symptomatic heart failure. In ... [more ▼]

Cardiac resynchronization therapy (CRT) is one of the most successful heart failure therapies to emerge in the last 25 years; it is applicable to > 25-30% of patients with symptomatic heart failure. In this article, we summarize the recommendations of the European Society of Cardiology of 2013 on cardiac resynchronization therapy. [less ▲]

Detailed reference viewed: 140 (3 ULg)